CORAL SPRINGS, Florida, May 22, 2014 /PRNewswire/ --
Healthcare companies' acquisitions, innovative therapies and state-of-the-art detection platforms making progress in sector: ImmunoClin Corporation (OTCBB: IMCL), Express Holding Company (NASDAQ: ESRX), RXi Pharmaceuticals Corporation (NASDAQ: RXII), Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS)
ImmunoClin Corporation (OTCQB: IMCL) is a U.S. healthcare company specializing in personalized medicine. ImmunoClin's DACTELLIGENCE™ technology is a newly patented concept in bio-sensing with a potential to challenge state-of-the-art detection platforms in multiple diagnostic fields. DACTELLIGENCE™ is expected to deliver pure electronic point-of-care devices capable of rapid detection while simultaneously processing data. The Company is pleased to welcome Mr. Railton Frith, an inventor of DACTELLIGENCE technology, to the Company's Scientific Advisory Board.
"Given the advancements made in the science and discovery of novel electronic and medical technologies, we are pleased to enlist Mr. Frith's expertise to join the race to revolutionize smart, electronic bio-sensing which holds incredible potential to benefit patients throughout the globe," said Mr. J. Scott Munro, CFO of ImmunoClin Corporation.
To read the full IMCL press release, please click here: http://finance.yahoo.com/news/immunoclin-corporation-imcl-announces-appointment-111200716.html
Mr. Frith led the team of professionals that designed the DACTELLIGENCE™ technology and has recently assigned his portion of the ownership to ImmunoClin. He was a founding member of the pioneering network company Zynar/Nestar Systems formed in the Silicon Valley by the Rank Organization.
Express Holding Company (NASDAQ: ESRX) provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. The company offers healthcare management and administration services on behalf of its clients. It operates in two segments, PBM and Other Business Operations. The company's PBM services comprise retail network pharmacy administration; home delivery pharmacy; benefit design consultation; drug utilization review; drug formulary management; clinical solutions to improve health outcomes; an array of Medicare Part D, Medicaid, and health insurance marketplace; specialty pharmacy services, such as the distribution of fertility pharmaceuticals that require special handling or packaging; bio- pharmaceutical services, including reimbursement and logistics solutions; group purchasing organization administration; and consumer health and drug information services. On Wednesday, ESRX closed up 1.01% on over 5.1 million shares traded.
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd-rxRNA®). The patent, titled "Reduced Size Self-Delivering RNAi Compounds", broadly covers both the composition and methods of use of RXi's self-delivering platform technology. The patent, once issued, will be scheduled to expire in 2029. This core patent, within RXi's intellectual property portfolio, is the foundation for RXI's self-delivering platform. The patent broadly protects RXi's sd-rxRNA technology, which facilitates the delivery of RNAi compounds to tissues and cells of interest in the absence of a delivery vehicle.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, recently announced an agreement to acquire a multifunctional manufacturing facility on 26 acres of land in Massachusetts. Sarepta intends to use the facility to manufacture investigational exon skipping therapies for Duchenne muscular dystrophy (DMD). The transaction comprises approximately $25 million in acquisition costs and planned enhancements, and is expected to close in July subject to conditions and extensions in the agreement. "This strategic acquisition complements our existing internal manufacturing capability and global network of suppliers," said Chris Garabedian, president and chief executive officer of Sarepta Therapeutics. "While we scale up to address the potential U.S. commercial demand for our lead product candidate eteplirsen in the event of an approval next year, the addition of internal resources will enhance our ability to advance the development of our broader exon skipping platform and explore the potential of our technology platform in other therapeutic areas."
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) recently announced positive top-line data from a Phase 2 comparator-controlled study evaluating the incidence of venous thrombolic events (VTE) in patients treated with ISIS-FXIRx undergoing total knee replacement surgery, or total knee arthroplasty (TKA). ISIS-FXIRx inhibits the production of Factor XI, a coagulation factor that plays a key role in thrombosis. In this study with a data cutoff of May 7, 2014, ISIS-FXIRx-treated patients experienced a dose-dependent decrease in VTEs. Patients treated with 300 mg of ISIS-FXIRx experienced a seven-fold (pRx had comparable incidence of VTEs compared to patients treated with enoxaparin. Patients treated with ISIS-FXIRx and enoxaparin experienced a very low rate of bleeding with ISIS-FXIRx-treated patients experiencing numerically fewer bleeding events compared to patients treated with enoxaparin. Isis plans to report the full data at an upcoming scientific meeting.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand seven hundred dollars for news coverage of the current press release issued by ImmunoClin Corporation. by a non-affiliated third party.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
Company: FN Media Group, LLC
Contact email: firstname.lastname@example.org
U.S. Phone: +1(954)345-0611
SOURCE FN Media Group, LLC